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• Patients were required to have either -≥2 T2DM diagnoses (ICD 10: E11.x or E14.x) and fewer type 1 diabetes mellitus diagnoses (ICD 10: E10.x) during the study period OR ≥1 T2DM diagnosis in study period and ≥1 non-insulin antidiabetic medication in the 6 months prior to first basal No insulin use on index date (other than basal insulin) or during the 6-month baseline period n=2,624
Age 18 years or older on the index date n=2,624
Presence of T2DM but no secondary diabetes or pregnancy diagnoses n=2,454
Continuously enrolled in the health plan during the study period n=827
Patients initiating non-mixed basal insulin; with the first date identified as index date 1
Insulin-naïve patients 2
Age restrictions 3
Evidence of T2DM and no other types of diabetes during 6 months prior to or 12 months following basal insulin initiation • All-cause and T2DM-related medical resource use and costs as well as pharmacy costs in the year after treatment initiation, adjusted for differences in baseline characteristics, were compared separately between interrupters and continuers, and discontinuers and continuers
• Propensity score-based inverse probability weighting 7 was used to adjust for differences in baseline characteristics between the groups -The propensity of being in a given cohort as a function of baseline characteristics observed baseline characteristics was estimated using a multinomial logistic regression model -Following the computation of propensity scores, each person was attributed a weight defined as the inverse of the propensity score for that person -Statistical comparisons were made using weighted t-tests for continuous measures and weighted chi-squared tests for categorical measures ♦ As a sensitivity, patterns of basal insulin use in the year after initiation were assessed allowing for <60-and <90-day gaps between the end of one and the beginning of another prescription
RESUlTS

Patterns of Basal Insulin Use During the Follow-up Period
♦ The majority of patients in the final analytic sample either interrupted (42%) or discontinued (22%) basal insulin therapy in the year after initiation ♦ Among interrupters and discontinuers, 48% and 54%, respectively had their first gap in therapy within the first 90 days of treatment initiation Early interruption and early discontinuation defined as having the first gap in insulin therapy within the first 90 days of treatment initiation
Time to Treatment Interruption and Discontinuation
♦ Using Kaplan-Meier analysis for the entire sample, the mean time to treatment interruption and discontinuation in the year after initiation were 7.4 months and 8.9 months respectively (Table 1) ♦ In addition, interrupters and discontinuers were significantly less likely to use non-insulin antihyperglycemic medications, outpatient services and primary care services before initiating insulin therapy but significantly more likely to have inpatient stays than continuers ( 95% CI = 95% Confidence Interval; † Relative to continuation; * Statistically significant at p<0.05; Note: The model also included other baseline comorbidity and medical resource use indicators; all of which were not significantly associated with treatment interruption and discontinuation. The year of index date was also included. Odds ratio <1 indicates increased likelihood of treatment continuation, and odds ratio>1 indicates increased likelihood of treatment interruption/discontinuation
Medical Resource Use and Costs in the Year after Treatment Initiation ♦ After accounting for underlying differences, continuers were significantly less likely to use all-cause and T2DM-related inpatient medical services in the year after treatment initiation compared with interrupters and discontinuers ( Table 3) ♦ In terms of costs, continuers had statistically significantly higher pharmacy costs than interrupters and discontinuers, but the medical and total costs were similar for the three cohorts ( Table 3) 
Sensitivity Analyses
♦ More T2DM patients in the final analytic sample are classified as continuers when allowing for longer gaps between the end of one and the beginning of another basal insulin prescription:
• Allowing for up to 60-day gaps in basal insulin use, 59.3% of the people are classified as continuers, 15.8% as interrupters, and 24.9% as discontinuers
• Allowing for up to 90-day gaps in basal insulin use classified 67.7% of the people as continuers, 7.9% as interrupters, and 24.4% as discontinuers SUMMARY ♦ During the 12 months after insulin initiation, 36% of all patients continued to use basal insulin, 42% had an interruption in treatment, and 22% discontinued therapy (i.e., had no fill) after the first gap
• Nearly half of the interrupters and discontinuers had their first gap within 90 days of insulin initiation ♦ Inpatient visits and using fewer other antihyperglycemic medications during baseline were associated with significantly higher likelihoods of treatment interruption and discontinuation ♦ Interrupters and discontinuers had significantly higher rates of hospitalizations during the year after treatment initiation; although the total medical costs were similar across the three cohorts
• These findings suggest that any interruption in treatment, independent of subsequent re-initiation is associated with outcomes requiring more acute care ♦ Although this is the first study to evaluate real-world patterns of basal insulin use and implications thereof in Japan, the key findings from this study are consistent with reports from similar studies in the US 4, 5 lIMITATIONS ♦ This analysis is subject to limitations associated with any inaccuracies or incompleteness of the ICD-10 codes and ATC codes used to identify diagnoses and medication use, as well as lack of clinical information (e.g., to assess blood glucose control)
♦ Factors associated with treatment interruption and discontinuation were based on the information captured in the data and do not reflect physician or patient preference on changing course of therapy ♦ Duration of insulin prescriptions were approximated based on the median number of days between consecutive basal insulin claims among all people in the sample stratified by units of insulin supplied, potentially resulting inaccurate estimates of actual days' supply of insulin ♦ Findings are limited to people aged ≤74 years who have employer-sponsored insurance in Japan and may not generalize to older populations CONClUSIONS ♦ In conclusion, the study findings indicate that substantial proportions of people with T2DM initiating basal insulin in Japan interrupt or discontinue treatment within the year after initiation ♦ Interrupters and discontinuers have higher rates of hospitalizations than continuers ♦ Further research is needed to understand the reasons behind basal insulin persistence and the implications thereof, to help clinicians manage care for T2DM more effectively
